Thursday, November 28, 2024 11:51:03 PM
According to Gemini: Yes, regulators do find gene and cell therapies more challenging to review than tablet-based medications. Here's why:
Novelty and Complexity: Gene and cell therapies utilize cutting-edge techniques, making their mechanisms of action more intricate.
Long-Term Effects: Assessing the lasting impact of these therapies is difficult due to their relatively recent introduction.
Safety Concerns: Potential risks like off-target effects or insertional mutagenesis require more scrutiny.
Personalized Nature: Some therapies are tailored to individuals, maing it harder to establish general safety and efficacy standards.
As for you putting tablets and gene and cell therapies in the same complexity bucket, I actually looked through mRNA patents casually, back when "news people" were selling us on safety and efficacy." 🤔🤥 I would challenge any physician or regulator to get past, say the first two or three pages, from the 93 representing, just one aspect of the patents, and explain it in simple terms. Forget the lie that they produced the vaccine in 9 months, while all the documents for anyone willing to do basic research will find mRNA vaccine research goes back to the late 90's. It was considered high risk for mutagenesis then, and there's never been long term safety studies to mitigate that concern. When Secretary Pompeo took to the podium at that time, as he was speaking about the circumstances then, as the vaccine was being rolled out, he said, "We're in the middle of a live exercise." Translation: "The population is the live trial." Get it?
It's taking nearly a year to approve the longest trialed, safest, most effective to date, nearly holistic treatment, and were to believe
not only did it not take regulators 3 or 5 years to review just the mRNA application, but even more absurd, that it took 9 months to put it together and release it en mass.
Simple minds die hard.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
